Bone metastases in patients with prostate cancer are a primary cause of pain, disability, and death. Body et al. review studies of bone-targeting agents in this setting, as well as the properties of both approved and novel systemic agents with regard to improving skeletal outcomes. They also discuss the place of these agents in the overall therapeutic strategy for patients with metastatic castration-resistant prostate cancer.
- Jean-Jacques Body
- Sandra Casimiro
- Luís Costa
